
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
January 29, 2025
Host Carmel Fisher interviews CEO Chris Bunka on Lexaria’s advancement in creating a superior absorption system for fat soluble nutrients.